产品说明书

Cefotaxime sodium

Print
Chemical Structure| 64485-93-4 同义名 : 头孢噻肟钠 ;Cefotaxim sodium;HR-756 sodium;CTX;Cefotaxime (sodium salt);HR-756
CAS号 : 64485-93-4
货号 : A468233
分子式 : C16H16N5NaO7S2
纯度 : 98%
分子量 : 477.447
MDL号 : MFCD00079073
存储条件：

粉末 Keep in dark place,Inert atmosphere,2-8°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 45 mg/mL(94.25 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 50 mg/mL(104.72 mM)，配合低频超声助溶
动物实验配方：
生物活性
描述 The cefotaxime sodium spectrum of activity is very broad and includes many common species and a variety of less frequently isolated pathogens. Cefotaxime was consistently active against Actinobacillus actinomycetemcomitans, Capnocytophaga spp, Eikenella corrodens, Erysipelothrix rhusiopathiae, Pasteurella multocida, Plesiomonas shigelloides, and Fusobacterium nucleatum[3]. The stability of cefotaxime sodium was dependent on the surface area of the excipient in contact with the drug[4]. Ceftriaxone may be more versatile having the additional apparent benefits of reducing other postoperative infections, being less dependent on metronidazole as an adjunct and providing a more effective prophylactic cover against Staphylococcus aureus[5]. Moreover, Ceftriaxone and cefotaxime are both effective in the treatment of bacterial meningitis[6].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT03067805 Sexual Infidelity ... 展开 >> Emotional Infidelity Jealousy 收起 << Not Applicable Recruiting November 2019 China, Sichuan ... 展开 >> School of Life Science and Technology, University of Electronic Science and Technology Recruiting Chengdu, Sichuan, China, 611731 Contact: Qin Li, Master       helenlee@uestc.edu.cn 收起 <<
NCT03053401 Post-operative Pain ... 展开 >> Quadriceps Muscle Strength 收起 << Not Applicable Recruiting June 30, 2019 United States, Ohio ... 展开 >> Akron Children's Hospital Recruiting Akron, Ohio, United States, 44308 Contact: Rami E Karroum, MD    330-543-8823    rkarroum@chmca.org    Contact: Ibrahim Farid, MD    330-543-8823    ifarid@chmca.org    Sub-Investigator: Ibrahim Farid, MD          Sub-Investigator: Paul Fleissner, MD          Sub-Investigator: Elizabeth Kendrick, MSN,RN          Sub-Investigator: Jonathan Klein, DO          Sub-Investigator: George Youssef, MD 收起 <<
NCT00726622 Colorectal Cancer Phase 3 Active, not recruiting - -
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.09mL

0.42mL

0.21mL

10.47mL

2.09mL

1.05mL

20.94mL

4.19mL

2.09mL
参考文献

[1]Woodfield JC, Van Rij AM, et al. A comparison of the prophylactic efficacy of ceftriaxone and cefotaxime in abdominal surgery. Am J Surg. 2003 Jan;185(1):45-9.

[2]Scholz H, Hofmann T, et al. Prospective comparison of ceftriaxone and cefotaxime for the short-term treatment of bacterial meningitis in children. Chemotherapy. 1998 Mar-Apr;44(2):142-7.

[3]Cormican MG, Jones RN. Antimicrobial activity of cefotaxime tested against infrequently isolated pathogenic species (unusual pathogens). Diagn Microbiol Infect Dis. 1995;22(1-2):43–48

[4]Al-Nimry SS, Alkhamis KA, Alzarieni KZ. The Effect of Specific Surface Area of Chitin-Metal Silicate Coprocessed Excipient on the Chemical Decomposition of Cefotaxime Sodium. J Pharm Sci. 2017;106(2):570–578

[5]Woodfield JC, Van Rij AM, Pettigrew RA, van der Linden AJ, Solomon C, Bolt D. A comparison of the prophylactic efficacy of ceftriaxone and cefotaxime in abdominal surgery. Am J Surg. 2003;185(1):45–49

[6]Scholz H, Hofmann T, Noack R, Edwards DJ, Stoeckel K. Prospective comparison of ceftriaxone and cefotaxime for the short-term treatment of bacterial meningitis in children. Chemotherapy. 1998;44(2):142–147